Number 5: The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar referencing Eylea (aflibercept).1 The new ...

ZUG, Switzerland, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, in collaboration with ...

Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American ...

Shares dropped by as much as one-quarter Thursday after the biotech shared longer-term results for a gene therapy it’s ...

Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today ...

One in seven patients with diabetes across the world resides in India, and one in three households has patients with the ...

This blockage may result in damage to the macula just described. Vabysmo is a treatment for wet AMD, DME, and macular edema from RVO that improves vision and helps slow vision loss. Vabysmo comes ...

Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with ...

Diana Do, MD, spoke with the Ophthalmology Times team about her presentation at the Retina Society meeting focusing on Population Pharmacokinetic Modeling and Simulation of Ocular Clearance for ...

Analyst Tim Chiang from Capital One Financial maintained a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report) and keeping ...